President Donald Trump at a meeting of the Coronavirus Task Force and pharmaceutical executives, March 2, 2020 (Kevin Dietsch/Sipa via AP Images)

As the cur­tain clos­es on the Trump pres­i­den­cy, biotech wres­tles with its fu­ture in a di­vid­ed Amer­i­ca

At 11 am af­ter the elec­tion, Sher­lock Bio­sciences CEO Rahul Dhan­da snuck in­to his of­fice and, in the cou­ple min­utes be­tween meet­ings, fired off an email to his 45 em­ploy­ees.

Dhan­da had walked in calm­ly at 7 am, but over the next four hours, he watched his em­ploy­ees slumped at their desks. The en­tire of­fice had sunk un­der a gen­er­al malaise. He asked a team mem­ber why they were so dis­traught. They looked up and asked: “Why are you so calm?”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.